Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 6/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7740151 | 0.97 | KDM4E (0.59) | KDM4EMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL7934318 | 0.95 | ALDH1A1 (0.51) | KDM4EMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL11165484 | 0.92 | ALDH1A1 (0.50) | KDM4EMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL11168545 | 0.91 | MEN1 (0.47) | KDM4EMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL8550832 | 0.91 | MEN1 (0.46) | KDM4EMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL4076285 | 0.90 | SIRT2 (0.49) | SIRT1SIRT5SIRT2SIRT3 | |
| SCHEMBL4727432 | 0.90 | SIRT2 (0.49) | SIRT1SIRT5SIRT2SIRT3 | |
| SCHEMBL29357392 | 0.90 | SIRT2 (0.49) | SIRT1SIRT5SIRT2SIRT3 | |
| SCHEMBL29404479 | 0.88 | KDM4E (0.56) | KDM4EMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL10727549 | 0.88 | SIRT2 (0.50) | KDM4EALDH1A1HPGDSIRT1SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128434-A1 | Alpha-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | ZIMMERMAN MARY P (US) | 2002-09-12 | — | — | US | disclosed |
| US-20020065264-A1 | Cysteine protease inhibitors containing heterocyclic leaving groups | ZIMMERMAN MARY P (US) | 2002-05-30 | — | — | US | disclosed |
| US-6297277-B1 | PEPTIDYL KETONES HAVING HETEROCYCLIC LEAVING GROUPS; CATHEPSIN INHIBITORS | PROTOTEK, INC. | 2001-10-02 | — | — | US | disclosed |
| US-6147188-A | IRREVERSIBLE CATHEPSIN OR CALPAIN INHIBITORS | PROTOTEK, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-5925772-A | ENZYME INHIBITORS FOR ANTIARTHRITIC AGENTS FROM HETEROCYCLIC PEPTIDES | PROTOTEK, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| EP-0731696-A4 | CYSTEINE PROTEASE INHIBITORS CONTAINING HETEROCYCLIC LEAVING GROUPS | PROTOTEK INC (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5714484-A | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | PROTOTEK, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5663380-A | ANTIARTHRITIC AGENTS; TREATMENT OF RHEUMATOID ARTHRITIS | PROTOTEK, INC. (US) | 1997-09-02 | — | — | US | disclosed |
| WO-1996040647-A1 | α-(1,3-DICARBONYLENOL ETHER) METHYL KETONES AS CYSTEINE PROTEASE INHIBITORS | PROTOTEK, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0731696-A1 | CYSTEINE PROTEASE INHIBITORS CONTAINING HETEROCYCLIC LEAVING GROUPS | PROTOTEK, INC. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5486623-A | Cysteine protease inhibitors containing heterocyclic leaving groups | PROTOTEK, INC. (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1995015749-A1 | CYSTEINE PROTEASE INHIBITORS CONTAINING HETEROCYCLIC LEAVING GROUPS | PROTOTEK, INC. (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128434-A1 | Alpha-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | CPN1, CTRL, SERPINB1 | KDM4E 1308/4885MEN1 2826/4885ALDH1A1 1415/4885 |
| US-20020065264-A1 | Cysteine protease inhibitors containing heterocyclic leaving groups | HPN, PREP, SPINT2 | KDM4E 3850/4885MEN1 3776/4885ALDH1A1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.